Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bupropion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 10/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 0.97 |
| ▸ | CHRNA1 | P02708 | 5/20 | 0.97 |
| ▸ | CHRNG | P07510 | 5/20 | 0.97 |
| ▸ | CHRNB1 | P11230 | 5/20 | 0.97 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.97 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.97 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.97 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.97 |
| ▸ | CHRND | Q07001 | 5/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.97 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | HRH1 | P35367 | 1/20 | 0.97 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.94 |
| ▸ | BLM | P54132 | 1/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bupropion SCHEMBL29388759 | 1.00 | SLC6A3 (0.97) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL60314 | 0.98 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL300444 | 0.98 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL38777 | 0.98 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL30679332 | 0.98 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL29354885 | 0.98 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL29424575 | 0.98 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL12499296 | 0.98 | SLC6A3 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL5608195 | 0.97 | SLC6A3 (0.97) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 | |
| Bupropion SCHEMBL41602 | 0.97 | SLC6A2 (1.00) | SLC6A3SLC6A2CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177326-A1 | THERAPEUTIC METHODS USING BUPROPION HYDROBROMIDE | PRICE RICHARD LOUIS (US) | 2025-06-05 | — | — | US | claimed |
| US-20250177327-A1 | THERAPEUTIC METHODS USING BUPROPION HYDROBROMIDE TO TREAT MAJOR DEPRESSIVE DISORDER | PRICE RICHARD LOUIS (US) | 2025-06-05 | — | — | US | claimed |
| US-12303473-B1 | Therapeutic methods using bupropion hydrobromide to treat Major Depressive Disorder | PRICE RICHARD LOUIS (US) | 2025-05-20 | — | — | US | claimed |
| US-12083080-B2 | Therapeutic methods using bupropion hydrobromide | PRICE RICHARD LOUIS (US) | 2024-09-10 | — | — | US | claimed |
| US-20240180853-A1 | THERAPEUTIC METHODS USING BUPROPION HYDROBROMIDE | PRICE RICHARD LOUIS (US) | 2024-06-06 | — | — | US | claimed |
| CN-115721724-A | Pharmaceutical composition containing secondary amine compound and preparation and application thereof | 山东威智中科药业有限公司 | 2023-03-03 | — | — | CN | claimed |
| WO-2017161387-A1 | COMPOSITIONS OF NATURAL EXTRACTS AND USE THEREOF IN METHODS FOR PREVENTING OR TREATING DISEASES | REID CHRISTOPHER BRIAN (US) | 2017-09-21 | — | — | WO | claimed |
| US-9504640-B2 | Modified release formulations of a bupropion salt | VALEANT PHARMACEUTICALS LUXEMBOURG S.Á.R.L. (LU) | 2016-11-29 | — | — | US | claimed |
| US-20150202147-A1 | Modified Release Formulations Of A Bupropion Salt | VALEANT INTERNATIONAL BERMUDA (BM) | 2015-07-23 | — | — | US | claimed |
| US-8932628-B2 | Modified release formulations of a bupropion salt | VALEANT INTERNATIONAL BERMUDA (BM) | 2015-01-13 | — | — | US | claimed |
| US-20080039441-A1 | Storage stability; combination forms with antidepressants, antiinflammatories, serotonin reuptake inhibitors, antiemetics, appetite modulators, antivirals, vasodilators and/or pain relievers | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2008-02-14 | — | — | US | claimed |
| US-20080033044-A1 | Crystal form; controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BIOAVAIL LABORATORIES (BB) | 2008-02-07 | — | — | US | claimed |
| US-20080033043-A1 | Crystal form; controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2008-02-07 | — | — | US | claimed |
| US-20070293584-A1 | hydrobromide salt; for treatment of depression, nicotine addiction and obesity | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-12-20 | — | — | US | claimed |
| US-20070281012-A1 | MODIFIED RELEASE FORMULATIONS OF A BUPROPION SALT | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-12-06 | — | — | US | claimed |
| US-20070276047-A1 | Administering bupropion hydrobromide to treat seasonal affective, obsessive compulsive, post-traumatic stress, psychological, respiratory system, attention deficit/hyperactivity, sexual or sleep disorders; anxiolytic agents, antidepressants; neurpathic pain, fibromyalgia, viricides; headaches, obesity | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-11-29 | — | — | US | claimed |
| US-20070269516-A1 | Controlled release matrix | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-11-22 | — | — | US | claimed |
| US-7241805-B2 | For therapy of depressive condition | BIOVAIL LABORATORIES, INC. (CA) | 2007-07-10 | — | — | US | claimed |
| US-20070027213-A1 | For therapy of depressive condition | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (CA) | 2007-02-01 | — | — | US | claimed |
| WO-2007002597-A2 | MODIFIED-RELEASE FORMULATIONS OF A BUPROPION SALT | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-01-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202147-A1 | Modified Release Formulations Of A Bupropion Salt | SLC6A2, SLC6A3, SLC6A11 | SLC6A3 2/4885SLC6A2 1/4885CHRNA1 308/4885 |
| US-20250177326-A1 | THERAPEUTIC METHODS USING BUPROPION HYDROBROMIDE | GABBR1, TRHDE, BDNF | SLC6A3 22/4885SLC6A2 8/4885CHRNA1 304/4885 |
| US-20070276047-A1 | Administering bupropion hydrobromide to treat seasonal affective, obsessive compulsive, post-traumatic stress, psychological, respiratory system, attention deficit/hyperactivity, sexual or sleep disorders; anxiolytic agents, antidepressants; neurpathic pain, fibromyalgia, viricides; headaches, obesity | HCRTR2, HCRTR1, SLC6A2 | SLC6A3 11/4885SLC6A2 3/4885CHRNA1 784/4885 |
| US-20080033044-A1 | Crystal form; controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BDNF, MME, SLC6A11 | SLC6A3 7/4885SLC6A2 4/4885CHRNA1 661/4885 |
| US-20070281012-A1 | MODIFIED RELEASE FORMULATIONS OF A BUPROPION SALT | SLC6A2, SLC6A3, SLC6A11 | SLC6A3 2/4885SLC6A2 1/4885CHRNA1 308/4885 |
| US-20080033043-A1 | Crystal form; controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl | BDNF, MME, SLC6A11 | SLC6A3 7/4885SLC6A2 4/4885CHRNA1 661/4885 |
| US-20250177327-A1 | THERAPEUTIC METHODS USING BUPROPION HYDROBROMIDE TO TREAT MAJOR DEPRESSIVE DISORDER | GABBR1, BDNF, GABBR2 | SLC6A3 24/4885SLC6A2 7/4885CHRNA1 279/4885 |
| US-20240180853-A1 | THERAPEUTIC METHODS USING BUPROPION HYDROBROMIDE | GABBR1, TRHDE, BDNF | SLC6A3 22/4885SLC6A2 8/4885CHRNA1 304/4885 |
| US-20080039441-A1 | Storage stability; combination forms with antidepressants, antiinflammatories, serotonin reuptake inhibitors, antiemetics, appetite modulators, antivirals, vasodilators and/or pain relievers | SLC6A4, HTR5A, SLC6A2 | SLC6A3 15/4885SLC6A2 3/4885CHRNA1 431/4885 |
| US-12083080-B2 | Therapeutic methods using bupropion hydrobromide | GABBR1, TRHDE, BDNF | SLC6A3 22/4885SLC6A2 8/4885CHRNA1 304/4885 |
| US-20070027213-A1 | For therapy of depressive condition | SLC6A2, SLC6A4, HTR5A | SLC6A3 4/4885SLC6A2 1/4885CHRNA1 144/4885 |
| US-20070269516-A1 | Controlled release matrix | SLC6A2, SLC6A11, SLC6A1 | SLC6A3 6/4885SLC6A2 1/4885CHRNA1 235/4885 |
| US-20070293584-A1 | hydrobromide salt; for treatment of depression, nicotine addiction and obesity | SLC6A3, SLC6A2, SLC6A4 | SLC6A3 1/4885SLC6A2 2/4885CHRNA1 52/4885 |
| US-12303473-B1 | Therapeutic methods using bupropion hydrobromide to treat Major Depressive Disorder | GABBR1, BDNF, GABBR2 | SLC6A3 24/4885SLC6A2 7/4885CHRNA1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.